SORA

Advancing, promoting and sharing knowledge of health through excellence in teaching, clinical practice and research into the prevention and treatment of illness

The importance for immunoregulation for long-term cancer control.

Fusi, A; Dalgleish, A (2017) The importance for immunoregulation for long-term cancer control. Future Oncol, 13 (18). ISSN 1744-8301 https://doi.org/10.2217/fon-2017-0085
SGUL Authors: Dalgleish, Angus George Fusi, Alberto

[img]
Preview
PDF Published Version
Available under License Creative Commons Attribution Non-commercial No Derivatives.

Download (1MB) | Preview
[img] Microsoft Word (.doc) Accepted Version
Available under License Creative Commons Attribution Non-commercial No Derivatives.

Download (432kB)
[img] Microsoft PowerPoint (Figure 1) Accepted Version
Available under License Creative Commons Attribution Non-commercial No Derivatives.

Download (37kB)

Abstract

Immune checkpoint blockades have recently emerged as a breakthrough treatment for solid tumors showing high response rates and long durability. In melanoma, the combination of ipilimumab with nivolumab showed high efficacy. However, still half the patients do not respond to this treatment. In order to increase the therapeutic ratio in melanoma and other cancers, different approaches are under evaluation. Three relevant questions are at the moment driving the research community: how to maximize benefit while minimizing toxicity; how to better identify patients who are more likely to benefit from immunotherapy; how to convert nonresponders into responders. In this review we summarize the most recent findings and we outline the most likely future challenges.

Item Type: Article
Additional Information: © Angus Dalgleish This work is licensed under the Attribution-NonCommercial-NoDerivatives 4.0 Unported License. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-nd/4.0/
Keywords: NSCLC, atezolizumab, biomarkers, checkpoint inhibitors, immunotherapy, ipilimumab, melanoma, nivolumab, pembrolizumab, Oncology & Carcinogenesis, 1112 Oncology And Carcinogenesis
SGUL Research Institute / Research Centre: Academic Structure > Infection and Immunity Research Institute (INII)
Journal or Publication Title: Future Oncol
ISSN: 1744-8301
Language: eng
Dates:
DateEvent
August 2017Published
4 August 2017Published Online
24 April 2017Accepted
Publisher License: Creative Commons: Attribution-Noncommercial-No Derivative Works 4.0
PubMed ID: 28776411
Go to PubMed abstract
URI: http://openaccess.sgul.ac.uk/id/eprint/108856
Publisher's version: https://doi.org/10.2217/fon-2017-0085

Actions (login required)

Edit Item Edit Item